Cover Page
Cover Page - shares | 3 Months Ended | |
Mar. 31, 2021 | Apr. 23, 2021 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2021 | |
Document Transition Report | false | |
Entity File Number | 001-33071 | |
Entity Registrant Name | EHEALTH, INC. | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 56-2357876 | |
Entity Address, Address Line One | 2625 AUGUSTINE DRIVE, SECOND FLOOR | |
Entity Address, City or Town | SANTA CLARA | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 95054 | |
City Area Code | 650 | |
Local Phone Number | 584-2700 | |
Title of 12(b) Security | Common Stock, par value $0.001 per share | |
Trading Symbol | EHTH | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding (in shares) | 26,091,024 | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2021 | |
Document Fiscal Period Focus | Q1 | |
Entity Central Index Key | 0001333493 | |
Current Fiscal Year End Date | --12-31 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Current assets: | ||
Cash and cash equivalents | $ 92,250 | $ 43,759 |
Short-term marketable securities | 33,922 | 49,620 |
Accounts receivable | 1,847 | 1,799 |
Contract assets – commissions receivable – current | 180,276 | 219,153 |
Prepaid expenses and other current assets | 12,325 | 16,661 |
Total current assets | 320,620 | 330,992 |
Contract assets – commissions receivable – non-current | 561,571 | 573,252 |
Property and equipment, net | 14,869 | 14,609 |
Operating lease right-of-use assets | 41,284 | 42,558 |
Restricted cash | 3,354 | 3,354 |
Intangible assets, net | 8,393 | 8,569 |
Goodwill | 40,233 | 40,233 |
Other assets | 27,471 | 26,455 |
Total assets | 1,017,795 | 1,040,022 |
Current liabilities: | ||
Accounts payable | 10,944 | 36,921 |
Accrued compensation and benefits | 24,630 | 20,542 |
Accrued marketing expenses | 11,076 | 17,788 |
Lease liabilities – current | 5,316 | 5,192 |
Deferred revenue | 877 | 308 |
Other current liabilities | 4,270 | 3,657 |
Total current liabilities | 57,113 | 84,408 |
Commitments and contingencies | ||
Deferred income taxes – non-current | 71,748 | 72,317 |
Lease liabilities – non-current | 39,984 | 41,369 |
Other non-current liabilities | 5,025 | 4,370 |
Stockholders’ equity: | ||
Common stock | 38 | 38 |
Additional paid-in capital | 728,213 | 721,013 |
Treasury stock, at cost | (199,998) | (199,998) |
Retained earnings | 315,355 | 316,155 |
Accumulated other comprehensive income | 317 | 350 |
Total stockholders’ equity | 843,925 | 837,558 |
Total liabilities and stockholders’ equity | $ 1,017,795 | $ 1,040,022 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Revenue: | ||
Total revenue | $ 134,214 | $ 106,408 |
Operating costs and expenses: | ||
Cost of revenue | 996 | 1,138 |
Marketing and advertising | 50,874 | 37,764 |
Customer care and enrollment | 34,162 | 30,535 |
Technology and content | 23,163 | 15,740 |
General and administrative | 23,054 | 19,653 |
Amortization of intangible assets | 176 | 547 |
Restructuring charges | 2,431 | 0 |
Total operating costs and expenses | 134,856 | 105,377 |
Income (loss) from operations | (642) | 1,031 |
Other income, net | 150 | 373 |
Income (loss) before provision for (benefit from) income taxes | (492) | 1,404 |
Provision for (benefit from) income taxes | 308 | (2,048) |
Net income (loss) | $ (800) | $ 3,452 |
Net income (loss) per share: | ||
Basic (in dollars per share) | $ (0.03) | $ 0.14 |
Diluted (in dollars per share) | $ (0.03) | $ 0.13 |
Weighted-average number of shares used in per share amounts: | ||
Basic (in shares) | 26,620 | 24,719 |
Diluted (in shares) | 26,620 | 26,179 |
Comprehensive income (loss): | ||
Net income (loss) | $ (800) | $ 3,452 |
Unrealized holding gain (loss) for available for sales debt securities, net of tax | (16) | 25 |
Foreign currency translation adjustment | (17) | (31) |
Comprehensive income (loss) | (833) | 3,446 |
Commission | ||
Revenue: | ||
Total revenue | 127,052 | 99,669 |
Other | ||
Revenue: | ||
Total revenue | $ 7,162 | $ 6,739 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands | Total | Cumulative effect from the adoption of ASU 2016-13 | Common Stock | Additional Paid-in Capital | Treasury Stock | Retained Earnings | Retained EarningsCumulative effect from the adoption of ASU 2016-13 | Accumulated Other Comprehensive Income |
Beginning balance (in shares) at Dec. 31, 2019 | 34,752 | 11,616 | ||||||
Beginning Balance at Dec. 31, 2019 | $ 527,164 | $ (1,147) | $ 35 | $ 455,159 | $ (199,998) | $ 271,852 | $ (1,147) | $ 116 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Issuance of common stock in connection with equity incentive plans (in shares) | 141 | |||||||
Issuance of common stock in connection with equity incentive plans | 1,091 | 1,091 | ||||||
Repurchase of shares to satisfy employee tax withholding obligations | (4,375) | (4,375) | ||||||
Repurchase of shares to satisfy employee tax withholding obligations (in shares) | 33 | |||||||
Stock-based compensation | 8,962 | 8,962 | ||||||
Other comprehensive income, net of tax | (6) | (6) | ||||||
Net income (loss) | 3,452 | 3,452 | ||||||
Shares issued in equity offering (in shares) | 2,070 | |||||||
Shares issued in equity offering | 228,024 | $ 2 | 228,022 | |||||
Settlement of earnout liability (in shares) | 295 | |||||||
Settlement of earnout liability | 28,521 | 28,521 | ||||||
Ending balance (in shares) at Mar. 31, 2020 | 37,258 | 11,649 | ||||||
Ending Balance at Mar. 31, 2020 | 791,686 | $ 37 | 717,380 | $ (199,998) | 274,157 | 110 | ||
Beginning balance (in shares) at Dec. 31, 2020 | 37,755 | 11,831 | ||||||
Beginning Balance at Dec. 31, 2020 | 837,558 | $ 38 | 721,013 | $ (199,998) | 316,155 | 350 | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Issuance of common stock in connection with equity incentive plans (in shares) | 238 | |||||||
Issuance of common stock in connection with equity incentive plans | 285 | 285 | ||||||
Repurchase of shares to satisfy employee tax withholding obligations | (5,037) | (5,037) | ||||||
Repurchase of shares to satisfy employee tax withholding obligations (in shares) | 81 | |||||||
Stock-based compensation | 11,952 | 11,952 | ||||||
Other comprehensive income, net of tax | (33) | (33) | ||||||
Net income (loss) | (800) | (800) | ||||||
Ending balance (in shares) at Mar. 31, 2021 | 37,993 | 11,912 | ||||||
Ending Balance at Mar. 31, 2021 | $ 843,925 | $ 38 | $ 728,213 | $ (199,998) | $ 315,355 | $ 317 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Operating activities: | ||
Net income (loss) | $ (800) | $ 3,452 |
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||
Depreciation and amortization | 1,138 | 823 |
Amortization of internally developed software | 2,806 | 1,501 |
Amortization of intangible assets | 176 | 547 |
Stock-based compensation expense | 11,402 | 8,714 |
Deferred income taxes | (570) | (2,141) |
Other non-cash items | 420 | 223 |
Changes in operating assets and liabilities: | ||
Accounts receivable | (48) | 1,664 |
Contract assets – commissions receivable | 50,635 | 26,873 |
Prepaid expenses and other assets | 4,225 | (159) |
Accounts payable | (25,826) | (16,279) |
Accrued compensation and benefits | 4,088 | (11,104) |
Accrued marketing expenses | (6,712) | (7,329) |
Deferred revenue | 570 | 113 |
Accrued expenses and other liabilities | 1,305 | 2,009 |
Net cash provided by operating activities | 42,809 | 8,907 |
Investing activities: | ||
Capitalized internal-use software and website development costs | (3,242) | (3,564) |
Purchases of property and equipment and other assets | (1,899) | (2,508) |
Purchases of marketable securities | (7,771) | (58,064) |
Proceeds from redemption and maturities of marketable securities | 23,409 | 0 |
Net cash provided by (used in) investing activities | 10,497 | (64,136) |
Financing activities: | ||
Proceeds from issuance of common stock, net of issuance costs | 0 | 228,024 |
Net proceeds from exercise of common stock options | 285 | 1,091 |
Repurchase of shares to satisfy employee tax withholding obligations | (5,037) | (4,375) |
Acquisition-related contingent payments | 0 | (8,751) |
Principal payments in connection with leases | (38) | (58) |
Net cash provided by (used in) financing activities | (4,790) | 215,931 |
Effect of exchange rate changes on cash, cash equivalents and restricted cash | (25) | (2) |
Net increase in cash, cash equivalents and restricted cash | 48,491 | 160,700 |
Cash, cash equivalents and restricted cash at beginning of period | 47,113 | 26,820 |
Cash, cash equivalents and restricted cash at end of period | $ 95,604 | $ 187,520 |
Summary of Business and Signifi
Summary of Business and Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2021 | |
Accounting Policies [Abstract] | |
Summary of Business and Significant Accounting Policies | Summary of Business and Significant Accounting Policies Description of Business – eHealth, Inc. (the “Company,” “eHealth,” “we” or “us”) is a leading health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. Our mission is to connect every person with the highest quality, most affordable health insurance and Medicare plans for their life circumstances. Our platform integrates proprietary and third-party developed educational content regarding health insurance plans with decision support tools to aid consumers in what has traditionally been a confusing and opaque health insurance purchasing process, and to help them obtain the health insurance products that meet their individual health and economic needs. Our omnichannel consumer engagement platform is designed to meet the consumer wherever they prefer to engage with us, and enables consumers to use our services online, through interactive chat, or by telephone with a licensed insurance agent. We have created a marketplace that offers consumers a broad choice of insurance products that includes thousands of Medicare Advantage, Medicare Supplement, Medicare Part D prescription drug, individual and family, small business and other ancillary health insurance products from over 200 health insurance carriers across all fifty states and the District of Columbia. Basis of Presentation – The accompanying condensed consolidated balance sheets as of March 31, 2021 and December 31, 2020 and the condensed consolidated statements of comprehensive income (loss), stockholders’ equity, and cash flows for the three months ended March 31, 2021 and 2020, respectively, are unaudited. The condensed consolidated balance sheet data as of December 31, 2020 was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the Securities and Exchange Commission on February 26, 2021. The accompanying financial statements and related notes should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K. The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. The condensed consolidated financial statements include the accounts of eHealth, Inc. and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Certain information and disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with those rules and regulations. Certain prior period amounts have been reclassified to conform with our current period presentation. However, we believe that the disclosures made are adequate to make the information not misleading. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020 and include all adjustments necessary for the fair presentation of our financial position as of March 31, 2021 and December 31, 2020, and our results of operations for the periods presented. Our financial position as of March 31, 2021 and results of operations and cash flows for the three months ended March 31, 2021 were not materially impacted by the COVID-19 pandemic but the Company is continuously assessing the evolving situation related to the pandemic. The results for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for any subsequent period or for the year ending December 31, 2021 and therefore should not be relied upon as an indicator of future results. Subsequent to the issuance of our consolidated financial statements for the year ended December 31, 2020, we identified certain errors, including a $3.0 million under-recognition of stock-based compensation expense and a $1.5 million over-recognition of licensing costs for the year ended December 31, 2020. We adjusted for these items in the first quarter of 2021 and the adjustments reduced our net income (loss) by approximately $1.5 million in our Condensed Consolidated Statement of Comprehensive Income (Loss) for the three months ended March 31, 2021. We evaluated the effects of these out-of-period adjustments, both qualitatively and quantitatively, and concluded that the errors and the correction thereof were immaterial both individually and in the aggregate to the current reporting period and the periods in which they originated, including quarterly reporting. Significant Accounting Policies, Estimates and Judgments – The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported and disclosed in the condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates, including those related to, but not limited to, the useful lives of intangible assets, fair value of investments, recoverability of intangible assets, the commissions we expect to collect for each approved member cohort, valuation allowance for deferred income taxes, provision (benefit) for income taxes and the assumptions used in determining stock-based compensation. We base our estimates of the carrying value of certain assets and liabilities on historical experience and on various other assumptions that we believe to be reasonable. Actual results may differ from these estimates. There have been no material changes to our significant accounting policies discussed in our Annual Report on Form 10-K for the year ended December 31, 2020. Seasonality – Open enrollment periods drive the seasonality of our business. A greater number of our Medicare-related health insurance plans are sold in our fourth quarter during the Medicare annual enrollment period when Medicare-eligible individuals are permitted to change their Medicare Advantage and Medicare Part D prescription drug coverage for the following year. As a result, our Medicare plan-related commission revenue is highest in our fourth quarter. Any changes or additional enrollment periods may change the seasonality of our business. For instance, due to the reintroduction of the Medicare Advantage open enrollment period that takes place in the first quarter of the year, our first quarter is generally the second-highest revenue generating quarter. The majority of our individual and family health insurance plans are sold in the fourth quarter during the annual open enrollment period as defined under the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act. Individuals and families generally are not able to purchase individual and family health insurance outside of these open enrollment periods, unless they qualify for a special enrollment period as a result of certain qualifying events, such as losing employer-sponsored health insurance or moving to another state due to the recent COVID-19 pandemic. Recently Adopted Accounting Pronouncement Income Taxes (Topic 740) – In December 2019, the FASB issued ASU No. 2019-12, Income Tax, Simplifying the Accounting for Income Taxes , which aims to simplify the accounting for income taxes. We adopted this guidance in the first quarter of 2021 and it did not have a material impact on our condensed consolidated financial statements. Codification Improvements – In October 2020, the FASB issued ASU No. 2020-10, Codification Improvements . ASU 2020-10 is intended to facilitate codification updates for technical corrections, such as conforming amendments, clarifications to guidance, simplifications to wording or structure of guidance, and other minor improvements. It contains amendments that improve the consistency of the codification by including all disclosure guidance in the appropriate disclosure section and other updates that varies in nature. We adopted this guidance in the first quarter of 2021 with no material impact on our condensed consolidated financial statements and disclosures. Debt with Conversion and Other Options (Topic 470) and Contracts in Entity's Own Equity (Topic 815) – In June 2020, the FASB issued ASU No. 2020-06 to simplify the accounting for convertible instruments and improve the usefulness and relevance of information regarding convertible instruments. This ASU reduces the number of accounting models for converting debt instruments and convertible preferred stock. ASU No. 2020-06 is effective for us in 2022, with early adoption permitted. We have early adopted this guidance in the first quarter of 2021 and it did not have a material impact on our condensed consolidated financial statements. |
Revenue
Revenue | 3 Months Ended |
Mar. 31, 2021 | |
Revenue from Contract with Customer [Abstract] | |
Revenue | Revenue Disaggregation of Revenue – The table below depicts the disaggregation of revenue by product and is consistent with how we evaluate our financial performance (in thousands): Three Months Ended March 31, 2021 2020 Medicare Medicare Advantage $ 103,525 $ 68,347 Medicare Supplement 8,222 15,170 Medicare Part D 1,736 5,661 Total Medicare 113,483 89,178 Individual and Family (1) Non-Qualified Health Plans 3,367 1,446 Qualified Health Plans 2,100 1,210 Total Individual and Family 5,467 2,656 Ancillary Short-term 1,756 2,216 Dental 1,728 743 Vision 205 243 Other 35 1,049 Total Ancillary 3,724 4,251 Small Business 3,223 2,971 Commission Bonus 1,155 613 Total Commission Revenue 127,052 99,669 Other Revenue Sponsorship and Advertising Revenue 5,814 5,890 Other 1,348 849 Total Other Revenue 7,162 6,739 Total Revenue $ 134,214 $ 106,408 _____________ (1) We define our individual and family plan offerings as major medical individual and family health insurance plans, which does not include Medicare-related, small business or ancillary plans. Individual and family health insurance plans include both qualified and non-qualified plans. Qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are offered through the government-run health insurance exchange in the relevant jurisdiction. Non-qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are not offered through the exchange in the relevant jurisdiction. Individuals that purchase non-qualified health plans cannot receive a subsidy in connection with the purchase of non-qualified plans. Commission revenue by segment is presented in the table below (in thousands): Three Months Ended March 31, 2021 2020 Medicare Commission Revenue from Members Approved During the Period (1) $ 114,678 $ 81,125 Net Commission Revenue from Members Approved in Prior Periods (2) 14 8,979 Total Medicare Segment Commission Revenue $ 114,692 $ 90,104 Individual, Family and Small Business Commission Revenue from Members Approved During the Period (1) $ 6,395 $ 5,796 Commission Revenue from Renewals of Small Business Members During the Period (3) 2,687 2,396 Net Commission Revenue from Members Approved in Prior Periods (2) 3,278 1,373 Total IFP/SMB Segment Commission Revenue $ 12,360 $ 9,565 Total Commission Revenue from Members Approved During the Period (1) $ 121,073 $ 86,921 Commission Revenue from Renewals of Small Business Members During the Period (3) 2,687 2,396 Total Net Commission Revenue from Members Approved in Prior Periods (2)(4) 3,292 10,352 Total Commission Revenue $ 127,052 $ 99,669 _____________ (1) These amounts include commission bonus revenue. (2) These amounts reflect our revised estimates of cash collections for certain members approved prior to the relevant reporting period that are recognized as adjustments to revenue within the relevant reporting period. The net adjustment revenue includes both increases in revenue for certain prior period cohorts as well as reductions in revenue for certain prior period cohorts. (3) Commission revenue from renewals of small business members during the period was previously included in net commission revenue from members approved in prior periods. However, starting in the first quarter of 2021, we enhanced our reporting by separately disclosing commission revenue from renewals of small business members during the period in a separate line item. (4) The impacts of total net commission revenue from members approved in prior periods were $0.12 and $0.42 per basic share, respectively, or $0.12 and $0.40 per diluted share, respectively, for the three months ended March 31, 2021 and 2020, respectively. The total reductions to revenue from members approved in prior periods were $0.9 million for the three months ended March 31, 2021 and immaterial for the three months ended March 31, 2020. These reductions to revenue primarily related to the Individual, Family and Small Business segment. |
Supplemental Financial Statemen
Supplemental Financial Statement Information | 3 Months Ended |
Mar. 31, 2021 | |
Balance Sheet Related Disclosures [Abstract] | |
Supplemental Financial Statement Information | Supplemental Financial Statement Information Cash, Cash Equivalents and Restricted Cash We consider all investments with an original maturity of 90 days or less from the date of purchase to be cash equivalents. Cash and cash equivalents are stated at fair value. We also invest in marketable securities that are measured and recorded at fair value. See Note 4 – Fair Value Measurements for further discussion about our marketable securities. Our cash, cash equivalent and restricted cash balances are summarized as follows (in thousands): March 31, 2021 December 31, 2020 Cash $ 72,326 $ 39,552 Cash equivalents 19,924 4,207 Cash and cash equivalents 92,250 43,759 Restricted cash 3,354 3,354 Total cash, cash equivalents and restricted cash $ 95,604 $ 47,113 As of March 31, 2021 and December 31, 2020, we had $3.4 million of restricted cash which was classified as a non-current asset on our Condensed Consolidated Balance Sheets. This amount collateralizes letters of credit related to certain lease commitments. Contract Assets and Accounts Receivable We do not require collateral or other security for our contract assets and accounts receivable. We believe the potential for collection issues with any of our customers was minimal as of March 31, 2021. We estimate an allowance for credit losses using relevant available information from internal and external sources, related to past events, current conditions, and reasonable and supportable forecasts. Specifically, for the purpose of measuring the probability of default parameters, we utilize Capital IQ’s, Standard & Poor’s and Moody’s analytics. Our estimates of loss given default are determined by using our historical collections data as well as historical information obtained through our research and review of other insurance related companies. Our estimated exposure at default is determined by applying these internal and external data sources to our commission receivable balances. As such, we apply an immediate reversion method and revert to historical loss information when computing our credit loss exposure. Credit loss expenses are assessed quarterly and included in general and administrative expense on our Condensed Consolidated Statement of Comprehensive Income (Loss). We considered the impact of recent events and global economic conditions when evaluating the appropriate adjustments to our allowance for credit losses as of March 31, 2021. Determining the extent of these adjustments in the three months ended March 31, 2021 was especially challenging because we do not have any historical loss information for a period of similar economic uncertainty. We also considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic. The change in the allowance for credit losses for the three months ended March 31, 2021 is summarized as follows (in thousands): Three Months Ended March 31, 2021 Beginning balance $ 2,026 Change in allowance (78) Ending balance $ 1,948 Our contract assets – commission receivable activities, net of credit loss allowances are summarized as follows (in thousands): Three Months Ended March 31, 2021 Medicare Segment IFP/SMB Segment Total Beginning balance $ 739,637 $ 52,768 $ 792,405 Commission revenue from members approved during the period 114,678 6,395 121,073 Commission revenue from renewals of small business members during the period (1) — 2,687 2,687 Net commission revenue adjustments from members approved in prior period 14 3,278 3,292 Cash receipts (165,520) (12,012) (177,532) Net change in credit loss allowance (72) (6) (78) Ending balance $ 688,737 $ 53,110 $ 741,847 Three Months Ended March 31, 2020 Medicare Segment IFP/SMB Segment Total Beginning balance $ 550,922 $ 38,300 $ 589,222 Commission revenue from members approved during the period 81,125 5,796 86,921 Commission revenue from renewals of small business members during the period (1) — 2,396 2,396 Net commission revenue adjustments from members approved in prior period 8,979 1,373 10,352 Cash receipts (112,731) (13,811) (126,542) Net change in credit loss allowance (1,574) (58) (1,632) Ending balance $ 526,721 $ 33,996 $ 560,717 _____________ (1) Commission revenue from renewals of small business members during the period was previously included in net commission revenue from members approved in prior periods. However, starting in the first quarter of 2021, we enhanced our reporting by separately disclosing commission revenue from renewals of small business members during the period in a separate line item. Credit Risk Our financial instruments that are exposed to concentrations of credit risk principally consist of cash, cash equivalents, marketable securities, contract assets – commissions receivable, and accounts receivable. We invest our cash and cash equivalents with major banks and financial institutions and, at times, such investments are in excess of federally insured limits. We also have deposits with major banks in China that are denominated in both U.S. dollars and Chinese Yuan Renminbi and are not insured by the U.S. federal government. The deposits in China were $3.5 million as of March 31, 2021. See Note 4 – Fair Value Measurements for more information regarding our marketable securities. We do not require collateral or other security for either our contract assets or accounts receivable. Carriers that represented 10% or more of our total contract assets and accounts receivable balance are summarized as of the dates presented below: March 31, 2021 December 31, 2020 UnitedHealthCare (1) 21 % 21 % Humana 21 % 21 % Aetna (1) 20 % 20 % Centene (1)(2) 12 % 11 % _____________ (1) Percentages include the carriers' subsidiaries. (2) Centene Corporation acquired WellCare Health Plans, Inc. in 2020, and the contract assets and accounts receivable of WellCare are included in the percentage calculation for March 31, 2021 and December 31, 2020. Prepaid Expenses and Other Current Assets – Our prepaid expenses and other current assets are summarized as of the periods presented as follows (in thousands): March 31, 2021 December 31, 2020 Prepaid maintenance contracts $ 6,583 $ 7,715 Prepaid expenses 4,095 6,628 Prepaid insurance 1,031 1,672 Others 616 646 Prepaid expenses and other current assets $ 12,325 $ 16,661 |
Fair Value Measurements
Fair Value Measurements | 3 Months Ended |
Mar. 31, 2021 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Fair Value Measurements We define fair value as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques we use to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. We classify the inputs used to measure fair value into the following hierarchy: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability. Level 3 Unobservable inputs for the asset or liability. Our financial assets measured at fair value on a recurring basis are summarized below by their classification within the fair value hierarchy as of the dates presented below (in thousands): March 31, 2021 Carrying Value Level 1 Level 2 Level 3 Total Assets Cash equivalents Money market funds $ 5,602 $ 5,602 $ — $ — $ 5,602 Commercial paper 14,322 — 14,322 — 14,322 Short-term marketable securities Agency bonds 26,826 — 26,826 — 26,826 Commercial paper 7,096 — 7,096 — 7,096 Total assets measured at fair value $ 53,846 $ 5,602 $ 48,244 $ — $ 53,846 December 31, 2020 Carrying Value Level 1 Level 2 Level 3 Total Assets Cash equivalents Money market funds $ 4,207 $ 4,207 $ — $ — $ 4,207 Short-term marketable securities Agency bonds 35,423 — 35,423 — 35,423 Commercial paper 14,197 — 14,197 — 14,197 Total assets measured at fair value $ 53,827 $ 4,207 $ 49,620 $ — $ 53,827 Our cash equivalents were invested in money market funds and commercial paper with original maturity of 90 days or less were classified as Level 1. We endeavor to utilize the best available information in measuring fair value. We used observable prices in active markets in determining the classification of our money market funds as Level 1. As of March 31, 2021, our Level 2 assets included our available for sale marketable securities, which consisted of commercial paper and agency bonds with maturity less than one year. We classify our marketable debt securities within Level 2 in the fair value hierarchy, because we use quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs to determine fair value. Our portfolio primarily consisted of financial instruments with a credit rating of AA or equivalent by S&P Rating and Moody's Investor Services. There were no transfers between the hierarchy levels during the three months ended March 31, 2021 and year ended December 31, 2020. The following table summarizes our cash equivalents and available-for-sale debt securities by contractual maturity (in thousands): As of March 31, 2021 Amortized Cost Fair Value Due in 1 year $ 53,827 $ 53,846 Unrealized gains and losses on available-for-sale debt securities that are not credit related are included in accumulated other comprehensive income and summarized as follows as of March 31, 2021 (in thousands): Amortized Cost Unrealized Gain Unrealized Loss Fair Value Cash equivalents Money market funds $ 5,602 $ — $ — $ 5,602 Commercial paper 14,323 — (1) 14,322 Short-term marketable securities Agency bonds 26,805 21 — 26,826 Commercial paper 7,097 — (1) 7,096 Total $ 53,827 $ 21 $ (2) $ 53,846 |
Equity
Equity | 3 Months Ended |
Mar. 31, 2021 | |
Stockholders' Equity Note [Abstract] | |
Equity | Equity Public Offering of Common Stock – Pursuant to an effective registration statement that was filed on December 17, 2018, and amended on January 22, 2019 and March 2, 2020, we entered into an underwriting agreement in March 2020 to issue a total of 2.1 million shares of common stock, which included the exercise in full of the underwriters’ option to purchase 0.3 million additional shares of common stock, at a price to the public of $115.00 per share in March 2020. Net proceeds from the offering were approximately $228.0 million after deducting underwriting discounts, commissions and expenses of the offering. Stock Repurchase Programs – We had no stock repurchase activity during the three months ended March 31, 2021. In addition to 10.7 million shares repurchased under our previous repurchase programs, we have in treasury 1.2 million shares as of March 31, 2021 that were previously surrendered by employees to satisfy tax withholding due in connection with the vesting of certain restricted stock units. As of March 31, 2021 and December 31, 2020, we had a total of 11.9 million shares and 11.8 million shares, respectively, held in treasury. For accounting purposes, common stock repurchased under our stock repurchase programs is recorded based upon the settlement date of the applicable trade. Such repurchased shares are held in treasury and are presented using the cost method. Stock-Based Compensation Expense – Our stock-based compensation expense is summarized as follows by award types (in thousands): Three Months Ended March 31, 2021 2020 Common stock options $ 180 $ 306 Restricted stock units* 10,719 8,408 ESPP 503 — Total stock-based compensation expense $ 11,402 $ 8,714 _________ * Amounts include market-based and performance-based RSUs. The following table summarizes stock-based compensation expense by operating function for the periods presented below (in thousands): Three Months Ended March 31, 2021 2020 Marketing and advertising $ 2,485 $ 1,730 Customer care and enrollment 469 662 Technology and content 2,743 1,617 General and administrative 5,705 4,705 Total stock-based compensation expense $ 11,402 $ 8,714 Amount capitalized in internal-use software 550 248 Total stock-based compensation $ 11,952 $ 8,962 |
Net Income (Loss) Per Share
Net Income (Loss) Per Share | 3 Months Ended |
Mar. 31, 2021 | |
Earnings Per Share [Abstract] | |
Net Income (Loss) Per Share | Net Income (Loss) Per Share Basic net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding for the period. Diluted net income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of common and common equivalent shares outstanding during the period. Diluted net income (loss) per share is computed giving effect to all potential dilutive common stock equivalent shares, including options, restricted stock units and shares to be issued under our ESPP. The dilutive effect of outstanding awards is reflected in diluted net income (loss) per share by application of the treasury stock method. The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands, except per share amounts): Three Months Ended March 31, 2021 2020 Numerator: Net income (loss) $ (800) $ 3,452 Denominator: Shares used in per share calculation – basic 26,620 24,719 Dilutive effect of common stock — 1,460 Shares used in diluted share calculation 26,620 26,179 Net income (loss) per share – basic $ (0.03) $ 0.14 Net income (loss) per share – diluted $ (0.03) $ 0.13 For each of the three months ended March 31, 2021 and 2020, we had securities outstanding that could potentially dilute per share amounts, but the shares from the assumed conversion or exercise of these securities were excluded in the computation of diluted net income (loss) per share as their effect would have been anti-dilutive. The number of outstanding anti-dilutive shares that were excluded from the computation of diluted net income (loss) per share consisted of the following (in thousands): Three Months Ended March 31, 2021 2020* Common stock options 363 n/a Restricted stock units 1,090 n/a ESPP 7 n/a Total 1,460 n/a _________ * There were no antidilutive shares for this period. |
Commitments and Contingencies
Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies Service and Licensing Obligations We have entered into service and licensing agreements with third party vendors to provide various services, including network access, equipment maintenance, and software licensing. As the benefits of these agreements are experienced uniformly over the applicable contractual periods, we record the related service and licensing expenses on a straight-line basis, although actual cash payment obligations under certain of these agreements fluctuate over the terms of the agreements. Our future minimum payments under non-cancellable contractual service and licensing obligations as of March 31, 2021 (in thousands): For the Years Ending December 31, Remainder of 2021 $ 4,246 2022 3,472 2023 2,745 2024 2,056 2025 1,353 Thereafter 1,353 Total $ 15,225 Operating Leases Refer to Note 9 – Leases for commitments related to our operating leases. Contingencies From time to time, we receive inquiries from governmental bodies and also may be subject to various legal proceedings and claims arising in the ordinary course of business. We assess contingencies to determine the degree of probability and range of possible loss for potential accrual in our condensed consolidated financial statements. An estimated loss contingency is accrued in the condensed consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. There was no material litigation-related accrual during the three months ended March 31, 2021. Legal proceedings or other contingencies could result in material costs, even if we ultimately prevail. Legal Proceedings Securities Class Action – On April 8, 2020 and April 30, 2020, two purported class action lawsuits were filed against us, our chief executive officer, Scott N. Flanders, our chief financial officer, Derek N. Yung, and our then-chief operating officer, David K. Francis, in the United States District Court for the Northern District of California. The cases are captioned Patel v. eHealth, Inc., et al ., Case No. 5:20-cv-02395 (N.D. Cal.) and Bertrand v. eHealth, Inc. et al., Case No. 4:20-cv-02967 (N.D. Cal.). The complaints allege, among other things, that we and Messrs. Flanders, Yung and Francis made materially false and misleading statements and/or failed to disclose material information regarding our accounting and modeling assumptions, rate of member churn and our profitability during the alleged class period of March 19, 2018 to April 7, 2020. The complaints allege that we and Messrs. Flanders, Yung and Francis violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. The complaints seek compensatory and (in the Patel lawsuit) punitive damages, attorneys’ fees and costs, and such other relief as the court deems proper. On June 24, 2020, the Court consolidated the above-referenced matters under the caption In re eHealth Securities Litig. , Master File No. 4:20-cv-02395-JST (N.D. Cal.). The Court also appointed a lead plaintiff and lead counsel for the consolidated matter. The lead plaintiff filed an amended complaint on August 25, 2020, which Defendants moved to dismiss. The motion to dismiss has been fully briefed. Derivative Actions – On July 7, 2020 and October 13, 2020, two derivative lawsuits were filed against our chief executive officer, Mr. Flanders, our chief financial officer, Mr. Yung, our then-chief operating officer, Mr. Francis, and the members of our Board of Directors (collectively, the “Individual Defendants”), in the United States District Court for the Northern District of California and the Superior Court of California, County of Santa Clara. The cases are captioned Chernet v. Flanders et al ., Case No. 3:20-cv-04477-SK (N.D. Cal.), and Lincolnshire Police Pension Fund v. Flanders et al. , Case No. 20CV371555 (Cal. Super. Ct.), and also name the Company as a nominal defendant. The complaints allege, among other things, that beginning on March 19, 2018, the Individual Defendants made or caused the Company to make materially false and misleading statements and/or failed to disclose material information regarding our accounting and modeling assumptions, rate of member churn, profitability, and internal controls. Both complaints purport to assert claims for breach of fiduciary duty, unjust enrichment and waste of corporate assets. The Chernet lawsuit also alleges that the Individual Defendants violated Sections 14(a), 10(b), and 20(a) of the Securities Exchange Act of 1934, and asserts claims for abuse of control and gross mismanagement. The complaints seek damages, restitution, attorneys’ fees and costs, and certain measures with respect to the Company’s corporate governance and internal procedures, and (in the Lincolnshire lawsuit) equitable and/or injunctive relief. The Chernet and Lincolnshire lawsuits have both been stayed pending the resolution of the motion to dismiss in the Securities Class Action, In re eHealth Securities Litig ., Master File No. 4:20-cv-02395-JST (N.D. Cal.). The Gonzalez and Le ’ Vias Complaints – On April 6, 2018, a former employee, Lupita Gonzalez, filed a complaint against us in the Superior Court of the State of California for the County of Sacramento (the “Gonzalez Complaint”). On July 1, 2019, two other current or former employees, Michael Le’Vias and Ramona Meadows, filed a related complaint against us and eHealth Ins. Serv. Co., in the Superior Court of the State of California for the County of Santa Clara (the “Le’Vias Complaint”). Both complaints asserted claims under the California Private Attorney General Act (“PAGA”) on behalf of all current and former hourly-paid or non-exempt employees who work or have worked for us in California, based on alleged failures to comply with California wage and hour laws. The parties have entered into a court-approved settlement agreement that resolves both matters related to the Gonzalez and Le'Vias Complaints, and Plaintiffs Michael Le’Vias and Ramona Meadows have sought dismissal with prejudice of the Le’Vias Complaint. Upon the completion of the distribution of the settlement funds in accordance with the settlement agreement and the court order approving the settlement agreement, the parties will seek a dismissal with prejudice of the Gonzalez Complaint. |
Segment and Geographic Informat
Segment and Geographic Information | 3 Months Ended |
Mar. 31, 2021 | |
Segment Reporting [Abstract] | |
Segment and Geographic Information | Segment and Geographic Information Operating Segments We report segment information based on how our chief executive officer, who is our chief operating decision maker ("CODM"), regularly reviews our operating results, allocates resources and makes decisions regarding our business operations. The performance measures of our segments include total revenue and profit. Our business structure is comprised of two operating segments: Medicare and Individual, Family and Small Business. Please refer to Note 1 – Summary of Business and Significant Accounting Policies of the Notes to Consolidated Financial Statements in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December 31, 2020 for our accounting policies relating to operating segments. The results of our operating segments are summarized for the periods presented below (in thousands): Three Months Ended March 31, 2021 2020 Revenue: Medicare $ 121,021 $ 96,151 Individual, Family and Small Business 13,193 10,257 Total revenue $ 134,214 $ 106,408 Segment profit: Medicare segment profit (1) $ 24,545 $ 23,136 Individual, Family and Small Business segment profit (1) 8,052 2,928 Total segment profit 32,597 26,064 Corporate (15,286) (13,448) Stock-based compensation expense (11,402) (8,714) Depreciation and amortization (2) (3,944) (2,324) Amortization of intangible assets (176) (547) Restructuring charges (2,431) — Other income, net 150 373 Income (loss) before provision for (benefit from) income taxes $ (492) $ 1,404 _____________ (1) During the first quarter of 2021, we revised the calculation of segment profit by excluding amortization of capitalized software development costs to enhance comparability of our financial metrics with peer companies. The amortization of capitalized software development costs were $2.8 million and $1.5 million for the first quarter of 2021 and 2020, respectively. (2) Depreciation and amortization has been adjusted to include amortization of software development costs. There were no inter-segment revenue transactions for the periods presented. With the exception of contract assets – commissions receivable, which is presented by segment in Note 3 – Supplemental Financial Statement Information , our CODM does not separately evaluate assets by segment, and therefore, assets by segment are not presented. Geographic Information Our long-lived assets primarily consist of property and equipment and internally-developed software. Our long-lived assets are attributed to the geographic location in which they are located. Long-lived assets by geographical area are summarized as follows (in thousands): March 31, 2021 December 31, 2020 United States $ 41,829 $ 40,500 China 511 565 Total $ 42,340 $ 41,065 Significant Customers Substantially all revenue for the three months ended March 31, 2021 and 2020 was generated from customers located in the United States. Carriers representing 10% or more of our total revenue are summarized as follows: Three Months Ended March 31, 2021 2020 UnitedHealthcare (1) 22 % 22 % Aetna (1) 21 % 15 % Humana 17 % 19 % Centene (2) 12 % 11 % __________ (1) Percentages include the carriers' subsidiaries. (2) Centene Corporation acquired WellCare Health Plans, Inc. in 2020, and the revenue of WellCare is included in the percentage calculation for March 31, 2021 and 2020. |
Leases
Leases | 3 Months Ended |
Mar. 31, 2021 | |
Leases [Abstract] | |
Leases | Leases Our leases have remaining lease terms of 3 to 9 years. Certain of these leases have free or escalating rent payment provisions. We recognize lease expense on a straight-line basis over the terms of the leases, although actual cash payment obligations under certain of these agreements fluctuate over the terms of the agreements. Most leases include options to renew, and the exercise of these options is at our discretion. Total operating lease expenses were $2.0 million and $2.1 million for the three months ended March 31, 2021 and 2020, respectively and sublease income was immaterial for both periods. The following table summarizes the lease-related assets and liabilities recorded on the Condensed Consolidated Balance Sheets as of the dates presented below (in thousands): March 31, 2021 December 31, 2020 Operating lease right-of-use assets $ 41,284 $ 42,558 Lease liabilities – current $ 5,316 $ 5,192 Lease liabilities – non-current 39,984 41,369 Total operating lease liabilities $ 45,300 $ 46,561 Supplemental information related to leases are as follows (in thousands): March 31, 2021 December 31, 2020 Operating cash outflows from operating leases $ 1,900 $ 7,090 Weighted-average remaining lease term of operating leases 7.0 years 7.2 years Weighted-average discount rate used to recognize operating lease right-of-use-assets 5.4 % 5.4 % As of March 31, 2021, maturities of operating lease liabilities are as follows (in thousands): Year ending December 31, Remainder of 2021 $ 5,744 2022 7,701 2023 8,033 2024 7,832 2025 8,009 Thereafter 19,407 Total lease payments (1) 56,726 Less imputed interest (11,426) Total $ 45,300 ____________ (1) Noncancellable sublease income for the remainder of 2021 and years ending December 31, 2022 and 2023 of $0.9 million, $0.4 million and $0.4 million, respectively, is not included in the table above. |
Restructuring
Restructuring | 3 Months Ended |
Mar. 31, 2021 | |
Restructuring and Related Activities [Abstract] | |
Restructuring | Restructuring In February 2021, we eliminated approximately 89 full-time positions, primarily in the United States, representing approximately 5% of our workforce, primarily within our customer care and enrollment group, and to a lesser extent, in our marketing and advertising, technology and content, and general and administrative groups. Total pre-tax restructuring charges for the three months ended March 31, 2021 were $2.4 million, which primarily related to employee termination benefits. Substantially all of the restructuring charges resulted in cash expenditures. The restructuring activities were completed by March 31, 2021. Accrued restructuring charges balance was $0.3 million as of March 31, 2021. |
Debt
Debt | 3 Months Ended |
Mar. 31, 2021 | |
Debt Disclosure [Abstract] | |
Debt | Debt On September 17, 2018, we entered into a Credit Agreement with Royal Bank of Canada (“RBC”), as administrative agent and collateral agent (the “Credit Agreement”). The Credit Agreement provides for a $40.0 million secured asset-backed revolving credit facility with a $5.0 million letter of credit sub-facility. On December 20, 2019, we amended our revolving credit facility agreement with RBC (the “Amendment”) and increased the borrowing amount from $40.0 to $75.0 million. The maturity date has been extended to December 20, 2022. The borrowing base under the Credit Agreement is comprised of an amount equal to (a) the lesser of (i) eighty percent (80%) of Eligible Commissions Receivables (as defined in the Credit Agreement) we actually collected during the immediately preceding period of three months or (ii) eighty percent (80%) of our Eligible Commission Receivables for the immediately succeeding period of three months, plus (b) fifty percent (50%) of our Eligible Commission Receivables for the immediately succeeding period of six months (excluding the immediately succeeding period of three months), in each case subject to reserves established by RBC (the “Borrowing Base”). The proceeds of the loans under the Credit Agreement may be used for working capital and general corporate purposes. The borrowers have the right to prepay the loans under the Credit Agreement in whole or in part at any time without penalty. Subject to availability under the Borrowing Base, amounts repaid may be reborrowed. Amounts not borrowed under the Credit Agreement will be subject to a commitment fee of 0.5% per annum on the daily unused portion of the credit facility, to be paid in arrears on the first business day of each calendar quarter. At the closing of the Credit Agreement, we paid a one-time facility fee of 1.75% of the total commitments of $40.0 million. We also paid a one-time closing fee of 0.5% of the new commitment of $75.0 million in connection with the Amendment. The Company is also obligated to pay other customary administration fees for a credit facility of this size and type. The availability under the credit facility was up to the lesser of $40.0 million or the Borrowing Base in the original credit agreement. The Amendment increased the availability up to the lesser of $75.0 million or the Borrowing Base, which may be reduced from time to time pursuant to the Credit Agreement. Financial covenants in the original Credit Agreement required that we maintain Excess Availability (as defined in the Credit Agreement) at or above $6.0 million at any time. The Amendment also changed the financial covenants to require us to maintain at least $6.0 million of Excess Availability at all times or, if greater, up to $11.3 million depending on our borrowing base as determined by eligible past and future commissions receivable. In addition, the Amendment also included changes in the payment conditions to, among other things, require us to have at least $10.0 million of liquidity or, if greater, up to $18.8 million depending on our borrowing base as determined by eligible past and future commissions receivable, in order for us to make certain permitted acquisitions, investments, distributions and payments of indebtedness. The Amendment also stated the seasonal amount thresholds used in connection with the cash dominion and field examination covenants in the Credit Agreement. We incurred $1.2 million of issuance costs in connection with the Credit Agreement, which were capitalized as part of other assets on our Consolidated Balance Sheet in the period we entered into the Credit Agreement. The Amendment did not change the interest rate. In connection with the Amendment, we incurred closing costs totaling $0.5 million, which were capitalized and recorded as other assets on our Condensed Consolidated Balance Sheet as of March 31, 2021. The remaining balance of unamortized issuance costs was $0.7 million as of March 31, 2021 and December 31, 2020. |
Income Taxes
Income Taxes | 3 Months Ended |
Mar. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes The following table summarizes our provision for (benefit from) income taxes and our effective tax rates for the periods presented below (in thousands, except effective tax rate): Three Months Ended March 31, 2021 2020 Income (loss) before provision for (benefit from) income taxes $ (492) $ 1,404 Provision for (benefit from) income taxes 308 (2,048) Effective tax rate (62.6) % (145.9) % For the three months ended March 31, 2021, we recognized a provision for income taxes of $0.3 million, representing an effective tax rate of (62.6)%, which was lower than the statutory federal tax rate due primarily to one-time state tax adjustments. For the three months ended March 31, 2020, we recognized a benefit from income taxes of $2.0 million, representing an effective tax rate of (145.9)%, which was lower than the statutory federal tax rate due primarily to stock-based compensation windfalls. Assessing the realizability of our deferred tax assets is dependent upon several factors, including the likelihood and amount, if any, of future taxable income in relevant jurisdictions during the periods in which those temporary differences become deductible. We forecast taxable income by considering all available positive and negative evidence, including our history of operating income and losses and our financial plans and estimates that we use to manage the business. These assumptions require significant judgment about future taxable income. As a result, the amount of deferred tax assets considered realizable is subject to adjustment in future periods if estimates of future taxable income change. We continue to recognize our |
Subsequent Event
Subsequent Event | 3 Months Ended |
Mar. 31, 2021 | |
Subsequent Events [Abstract] | |
Subsequent Event | Subsequent Event On April 30, 2021, we issued and sold to Echelon Health SPV, LP ("H.I.G."), an investment vehicle of H.I.G. Capital, in a private placement, 2,250,000 shares of our newly designated Series A convertible preferred stock, in par value of $0.001 per share (“Series A Preferred Stock”), at an aggregate purchase price of $225.0 million, at a price of $100 per share. We received $216.2 million in proceeds from the private placement with H.I.G., net of sales commissions and certain transaction fees. |
Summary of Business and Signi_2
Summary of Business and Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2021 | |
Accounting Policies [Abstract] | |
Description of Business | Description of Business – eHealth, Inc. (the “Company,” “eHealth,” “we” or “us”) is a leading health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. Our mission is to connect every person with the highest quality, most affordable health insurance and Medicare plans for their life circumstances. Our platform integrates proprietary and third-party developed educational content regarding health insurance plans with decision support tools to aid consumers in what has traditionally been a confusing and opaque health insurance purchasing process, and to help them obtain the health insurance products that meet their individual health and economic needs. Our omnichannel consumer engagement platform is designed to meet the consumer wherever they prefer to engage with us, and enables consumers to use our services online, through interactive chat, or by telephone with a licensed insurance agent. We have created a marketplace that offers consumers a broad choice of insurance products that includes thousands of Medicare Advantage, Medicare Supplement, Medicare Part D prescription drug, individual and family, small business and other ancillary health insurance products from over 200 health insurance carriers across all fifty states and the District of Columbia. |
Basis of Presentation | Basis of Presentation – The accompanying condensed consolidated balance sheets as of March 31, 2021 and December 31, 2020 and the condensed consolidated statements of comprehensive income (loss), stockholders’ equity, and cash flows for the three months ended March 31, 2021 and 2020, respectively, are unaudited. The condensed consolidated balance sheet data as of December 31, 2020 was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the Securities and Exchange Commission on February 26, 2021. The accompanying financial statements and related notes should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K. The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. The condensed consolidated financial statements include the accounts of eHealth, Inc. and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Certain information and disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with those rules and regulations. Certain prior period amounts have been reclassified to conform with our current period presentation. However, we believe that the disclosures made are adequate to make the information not misleading. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020 and include all adjustments necessary for the fair presentation of our financial position as of March 31, 2021 and December 31, 2020, and our results of operations for the periods presented. Our financial position as of March 31, 2021 and results of operations and cash flows for the three months ended March 31, 2021 were not materially impacted by the COVID-19 pandemic but the Company is continuously assessing the evolving situation related to the pandemic. The results for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for any subsequent period or for the year ending December 31, 2021 and therefore should not be relied upon as an indicator of future results. Subsequent to the issuance of our consolidated financial statements for the year ended December 31, 2020, we identified certain errors, including a $3.0 million under-recognition of stock-based compensation expense and a $1.5 million over-recognition of licensing costs for the year ended December 31, 2020. We adjusted for these items in the first quarter of 2021 and the adjustments reduced our net income (loss) by approximately $1.5 million in our Condensed Consolidated Statement of Comprehensive Income (Loss) for the three months ended March 31, 2021. We evaluated the effects of these out-of-period adjustments, both qualitatively and quantitatively, and concluded that the errors and the correction thereof were immaterial both individually and in the aggregate to the current reporting period and the periods in which they originated, including quarterly reporting. |
Significant Accounting Policies, Estimates and Judgments | Significant Accounting Policies, Estimates and Judgments – The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates, judgments and |
Seasonality | Seasonality – Open enrollment periods drive the seasonality of our business. A greater number of our Medicare-related health insurance plans are sold in our fourth quarter during the Medicare annual enrollment period when Medicare-eligible individuals are permitted to change their Medicare Advantage and Medicare Part D prescription drug coverage for the following year. As a result, our Medicare plan-related commission revenue is highest in our fourth quarter. Any changes or additional enrollment periods may change the seasonality of our business. For instance, due to the reintroduction of the Medicare Advantage open enrollment period that takes place in the first quarter of the year, our first quarter is generally the second-highest revenue generating quarter. The majority of our individual and family health insurance plans are sold in the fourth quarter during the annual open enrollment period as defined under the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act. Individuals and families generally are not able to purchase individual and family health insurance outside of these open enrollment periods, unless they qualify for a special enrollment period as a result of certain qualifying events, such as losing employer-sponsored health insurance or moving to another state due to the recent COVID-19 pandemic. |
Recently Adopted Accounting Pronouncement | Recently Adopted Accounting Pronouncement Income Taxes (Topic 740) – In December 2019, the FASB issued ASU No. 2019-12, Income Tax, Simplifying the Accounting for Income Taxes , which aims to simplify the accounting for income taxes. We adopted this guidance in the first quarter of 2021 and it did not have a material impact on our condensed consolidated financial statements. Codification Improvements – In October 2020, the FASB issued ASU No. 2020-10, Codification Improvements . ASU 2020-10 is intended to facilitate codification updates for technical corrections, such as conforming amendments, clarifications to guidance, simplifications to wording or structure of guidance, and other minor improvements. It contains amendments that improve the consistency of the codification by including all disclosure guidance in the appropriate disclosure section and other updates that varies in nature. We adopted this guidance in the first quarter of 2021 with no material impact on our condensed consolidated financial statements and disclosures. Debt with Conversion and Other Options (Topic 470) and Contracts in Entity's Own Equity (Topic 815) – In June 2020, the FASB issued ASU No. 2020-06 to simplify the accounting for convertible instruments and improve the usefulness and relevance of information regarding convertible instruments. This ASU reduces the number of accounting models for converting debt instruments and convertible preferred stock. ASU No. 2020-06 is effective for us in 2022, with early adoption permitted. We have early adopted this guidance in the first quarter of 2021 and it did not have a material impact on our condensed consolidated financial statements. |
Revenue (Tables)
Revenue (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Revenue from Contract with Customer [Abstract] | |
Disaggregation of Revenue by Segment | Disaggregation of Revenue – The table below depicts the disaggregation of revenue by product and is consistent with how we evaluate our financial performance (in thousands): Three Months Ended March 31, 2021 2020 Medicare Medicare Advantage $ 103,525 $ 68,347 Medicare Supplement 8,222 15,170 Medicare Part D 1,736 5,661 Total Medicare 113,483 89,178 Individual and Family (1) Non-Qualified Health Plans 3,367 1,446 Qualified Health Plans 2,100 1,210 Total Individual and Family 5,467 2,656 Ancillary Short-term 1,756 2,216 Dental 1,728 743 Vision 205 243 Other 35 1,049 Total Ancillary 3,724 4,251 Small Business 3,223 2,971 Commission Bonus 1,155 613 Total Commission Revenue 127,052 99,669 Other Revenue Sponsorship and Advertising Revenue 5,814 5,890 Other 1,348 849 Total Other Revenue 7,162 6,739 Total Revenue $ 134,214 $ 106,408 _____________ (1) We define our individual and family plan offerings as major medical individual and family health insurance plans, which does not include Medicare-related, small business or ancillary plans. Individual and family health insurance plans include both qualified and non-qualified plans. Qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are offered through the government-run health insurance exchange in the relevant jurisdiction. Non-qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are not offered through the exchange in the relevant jurisdiction. Individuals that purchase non-qualified health plans cannot receive a subsidy in connection with the purchase of non-qualified plans. Commission revenue by segment is presented in the table below (in thousands): Three Months Ended March 31, 2021 2020 Medicare Commission Revenue from Members Approved During the Period (1) $ 114,678 $ 81,125 Net Commission Revenue from Members Approved in Prior Periods (2) 14 8,979 Total Medicare Segment Commission Revenue $ 114,692 $ 90,104 Individual, Family and Small Business Commission Revenue from Members Approved During the Period (1) $ 6,395 $ 5,796 Commission Revenue from Renewals of Small Business Members During the Period (3) 2,687 2,396 Net Commission Revenue from Members Approved in Prior Periods (2) 3,278 1,373 Total IFP/SMB Segment Commission Revenue $ 12,360 $ 9,565 Total Commission Revenue from Members Approved During the Period (1) $ 121,073 $ 86,921 Commission Revenue from Renewals of Small Business Members During the Period (3) 2,687 2,396 Total Net Commission Revenue from Members Approved in Prior Periods (2)(4) 3,292 10,352 Total Commission Revenue $ 127,052 $ 99,669 _____________ (1) These amounts include commission bonus revenue. (2) These amounts reflect our revised estimates of cash collections for certain members approved prior to the relevant reporting period that are recognized as adjustments to revenue within the relevant reporting period. The net adjustment revenue includes both increases in revenue for certain prior period cohorts as well as reductions in revenue for certain prior period cohorts. (3) Commission revenue from renewals of small business members during the period was previously included in net commission revenue from members approved in prior periods. However, starting in the first quarter of 2021, we enhanced our reporting by separately disclosing commission revenue from renewals of small business members during the period in a separate line item. (4) The impacts of total net commission revenue from members approved in prior periods were $0.12 and $0.42 per basic share, respectively, or $0.12 and $0.40 per diluted share, respectively, for the three months ended March 31, 2021 and 2020, respectively. The total reductions to revenue from members approved in prior periods were $0.9 million for the three months ended March 31, 2021 and immaterial for the three months ended March 31, 2020. These reductions to revenue primarily related to the Individual, Family and Small Business segment. |
Supplemental Financial Statem_2
Supplemental Financial Statement Information (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Balance Sheet Related Disclosures [Abstract] | |
Schedule Of Cash, Cash Equivalents and Restricted Cash | Our cash, cash equivalent and restricted cash balances are summarized as follows (in thousands): March 31, 2021 December 31, 2020 Cash $ 72,326 $ 39,552 Cash equivalents 19,924 4,207 Cash and cash equivalents 92,250 43,759 Restricted cash 3,354 3,354 Total cash, cash equivalents and restricted cash $ 95,604 $ 47,113 |
Schedule of Cash, Cash Equivalents and Restricted Cash | Our cash, cash equivalent and restricted cash balances are summarized as follows (in thousands): March 31, 2021 December 31, 2020 Cash $ 72,326 $ 39,552 Cash equivalents 19,924 4,207 Cash and cash equivalents 92,250 43,759 Restricted cash 3,354 3,354 Total cash, cash equivalents and restricted cash $ 95,604 $ 47,113 |
Schedule of Change in Allowance for Credit Loss | The change in the allowance for credit losses for the three months ended March 31, 2021 is summarized as follows (in thousands): Three Months Ended March 31, 2021 Beginning balance $ 2,026 Change in allowance (78) Ending balance $ 1,948 |
Schedule of Contract Assets - Commissions Receivable | Our contract assets – commission receivable activities, net of credit loss allowances are summarized as follows (in thousands): Three Months Ended March 31, 2021 Medicare Segment IFP/SMB Segment Total Beginning balance $ 739,637 $ 52,768 $ 792,405 Commission revenue from members approved during the period 114,678 6,395 121,073 Commission revenue from renewals of small business members during the period (1) — 2,687 2,687 Net commission revenue adjustments from members approved in prior period 14 3,278 3,292 Cash receipts (165,520) (12,012) (177,532) Net change in credit loss allowance (72) (6) (78) Ending balance $ 688,737 $ 53,110 $ 741,847 Three Months Ended March 31, 2020 Medicare Segment IFP/SMB Segment Total Beginning balance $ 550,922 $ 38,300 $ 589,222 Commission revenue from members approved during the period 81,125 5,796 86,921 Commission revenue from renewals of small business members during the period (1) — 2,396 2,396 Net commission revenue adjustments from members approved in prior period 8,979 1,373 10,352 Cash receipts (112,731) (13,811) (126,542) Net change in credit loss allowance (1,574) (58) (1,632) Ending balance $ 526,721 $ 33,996 $ 560,717 _____________ |
Schedule of Credit Risk | Carriers that represented 10% or more of our total contract assets and accounts receivable balance are summarized as of the dates presented below: March 31, 2021 December 31, 2020 UnitedHealthCare (1) 21 % 21 % Humana 21 % 21 % Aetna (1) 20 % 20 % Centene (1)(2) 12 % 11 % _____________ (1) Percentages include the carriers' subsidiaries. (2) Centene Corporation acquired WellCare Health Plans, Inc. in 2020, and the contract assets and accounts receivable of WellCare are included in the percentage calculation for March 31, 2021 and December 31, 2020. |
Schedule Of Prepaid Expenses And Other Current Assets | Our prepaid expenses and other current assets are summarized as of the periods presented as follows (in thousands): March 31, 2021 December 31, 2020 Prepaid maintenance contracts $ 6,583 $ 7,715 Prepaid expenses 4,095 6,628 Prepaid insurance 1,031 1,672 Others 616 646 Prepaid expenses and other current assets $ 12,325 $ 16,661 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | We classify the inputs used to measure fair value into the following hierarchy: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability. Level 3 Unobservable inputs for the asset or liability. |
Summary of Financial Assets Measured at Fair Value on a Recurring Basis | Our financial assets measured at fair value on a recurring basis are summarized below by their classification within the fair value hierarchy as of the dates presented below (in thousands): March 31, 2021 Carrying Value Level 1 Level 2 Level 3 Total Assets Cash equivalents Money market funds $ 5,602 $ 5,602 $ — $ — $ 5,602 Commercial paper 14,322 — 14,322 — 14,322 Short-term marketable securities Agency bonds 26,826 — 26,826 — 26,826 Commercial paper 7,096 — 7,096 — 7,096 Total assets measured at fair value $ 53,846 $ 5,602 $ 48,244 $ — $ 53,846 December 31, 2020 Carrying Value Level 1 Level 2 Level 3 Total Assets Cash equivalents Money market funds $ 4,207 $ 4,207 $ — $ — $ 4,207 Short-term marketable securities Agency bonds 35,423 — 35,423 — 35,423 Commercial paper 14,197 — 14,197 — 14,197 Total assets measured at fair value $ 53,827 $ 4,207 $ 49,620 $ — $ 53,827 |
Summary of Contractual Maturities | The following table summarizes our cash equivalents and available-for-sale debt securities by contractual maturity (in thousands): As of March 31, 2021 Amortized Cost Fair Value Due in 1 year $ 53,827 $ 53,846 |
Summary of Unrealized Gains and Losses | Unrealized gains and losses on available-for-sale debt securities that are not credit related are included in accumulated other comprehensive income and summarized as follows as of March 31, 2021 (in thousands): Amortized Cost Unrealized Gain Unrealized Loss Fair Value Cash equivalents Money market funds $ 5,602 $ — $ — $ 5,602 Commercial paper 14,323 — (1) 14,322 Short-term marketable securities Agency bonds 26,805 21 — 26,826 Commercial paper 7,097 — (1) 7,096 Total $ 53,827 $ 21 $ (2) $ 53,846 |
Equity (Tables)
Equity (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Stockholders' Equity Note [Abstract] | |
Schedule Of Stock-Based Compensation Expense By Award Type | Our stock-based compensation expense is summarized as follows by award types (in thousands): Three Months Ended March 31, 2021 2020 Common stock options $ 180 $ 306 Restricted stock units* 10,719 8,408 ESPP 503 — Total stock-based compensation expense $ 11,402 $ 8,714 _________ * Amounts include market-based and performance-based RSUs. |
Schedule Of Stock-Based Compensation Expense By Operating Function | The following table summarizes stock-based compensation expense by operating function for the periods presented below (in thousands): Three Months Ended March 31, 2021 2020 Marketing and advertising $ 2,485 $ 1,730 Customer care and enrollment 469 662 Technology and content 2,743 1,617 General and administrative 5,705 4,705 Total stock-based compensation expense $ 11,402 $ 8,714 Amount capitalized in internal-use software 550 248 Total stock-based compensation $ 11,952 $ 8,962 |
Net Income (Loss) Per Share (Ta
Net Income (Loss) Per Share (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Earnings Per Share [Abstract] | |
Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share | The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands, except per share amounts): Three Months Ended March 31, 2021 2020 Numerator: Net income (loss) $ (800) $ 3,452 Denominator: Shares used in per share calculation – basic 26,620 24,719 Dilutive effect of common stock — 1,460 Shares used in diluted share calculation 26,620 26,179 Net income (loss) per share – basic $ (0.03) $ 0.14 Net income (loss) per share – diluted $ (0.03) $ 0.13 |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share | The number of outstanding anti-dilutive shares that were excluded from the computation of diluted net income (loss) per share consisted of the following (in thousands): Three Months Ended March 31, 2021 2020* Common stock options 363 n/a Restricted stock units 1,090 n/a ESPP 7 n/a Total 1,460 n/a _________ * There were no antidilutive shares for this period. |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Schedule of Future Minimum Rental Payments for Contractual Obligations | Our future minimum payments under non-cancellable contractual service and licensing obligations as of March 31, 2021 (in thousands): For the Years Ending December 31, Remainder of 2021 $ 4,246 2022 3,472 2023 2,745 2024 2,056 2025 1,353 Thereafter 1,353 Total $ 15,225 |
Segment and Geographic Inform_2
Segment and Geographic Information (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Segment Reporting [Abstract] | |
Schedule of Segment Reporting Information, by Segment | The results of our operating segments are summarized for the periods presented below (in thousands): Three Months Ended March 31, 2021 2020 Revenue: Medicare $ 121,021 $ 96,151 Individual, Family and Small Business 13,193 10,257 Total revenue $ 134,214 $ 106,408 Segment profit: Medicare segment profit (1) $ 24,545 $ 23,136 Individual, Family and Small Business segment profit (1) 8,052 2,928 Total segment profit 32,597 26,064 Corporate (15,286) (13,448) Stock-based compensation expense (11,402) (8,714) Depreciation and amortization (2) (3,944) (2,324) Amortization of intangible assets (176) (547) Restructuring charges (2,431) — Other income, net 150 373 Income (loss) before provision for (benefit from) income taxes $ (492) $ 1,404 _____________ (1) During the first quarter of 2021, we revised the calculation of segment profit by excluding amortization of capitalized software development costs to enhance comparability of our financial metrics with peer companies. The amortization of capitalized software development costs were $2.8 million and $1.5 million for the first quarter of 2021 and 2020, respectively. |
Schedule Of Long Lived Assets By Geographical Areas | Long-lived assets by geographical area are summarized as follows (in thousands): March 31, 2021 December 31, 2020 United States $ 41,829 $ 40,500 China 511 565 Total $ 42,340 $ 41,065 |
Schedule Of Revenue By Major Customers | Carriers representing 10% or more of our total revenue are summarized as follows: Three Months Ended March 31, 2021 2020 UnitedHealthcare (1) 22 % 22 % Aetna (1) 21 % 15 % Humana 17 % 19 % Centene (2) 12 % 11 % __________ (1) Percentages include the carriers' subsidiaries. (2) Centene Corporation acquired WellCare Health Plans, Inc. in 2020, and the revenue of WellCare is included in the percentage calculation for March 31, 2021 and 2020. |
Leases (Tables)
Leases (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Leases [Abstract] | |
Schedule of Supplemental Balance Sheet Information | The following table summarizes the lease-related assets and liabilities recorded on the Condensed Consolidated Balance Sheets as of the dates presented below (in thousands): March 31, 2021 December 31, 2020 Operating lease right-of-use assets $ 41,284 $ 42,558 Lease liabilities – current $ 5,316 $ 5,192 Lease liabilities – non-current 39,984 41,369 Total operating lease liabilities $ 45,300 $ 46,561 |
Schedule of Supplemental Information | Supplemental information related to leases are as follows (in thousands): March 31, 2021 December 31, 2020 Operating cash outflows from operating leases $ 1,900 $ 7,090 Weighted-average remaining lease term of operating leases 7.0 years 7.2 years Weighted-average discount rate used to recognize operating lease right-of-use-assets 5.4 % 5.4 % |
Schedule of Operating Lease Maturities | As of March 31, 2021, maturities of operating lease liabilities are as follows (in thousands): Year ending December 31, Remainder of 2021 $ 5,744 2022 7,701 2023 8,033 2024 7,832 2025 8,009 Thereafter 19,407 Total lease payments (1) 56,726 Less imputed interest (11,426) Total $ 45,300 ____________ (1) Noncancellable sublease income for the remainder of 2021 and years ending December 31, 2022 and 2023 of $0.9 million, $0.4 million and $0.4 million, respectively, is not included in the table above. |
Income Taxes (Tables)
Income Taxes (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
Schedule Of Components Of Income Tax Expense | The following table summarizes our provision for (benefit from) income taxes and our effective tax rates for the periods presented below (in thousands, except effective tax rate): Three Months Ended March 31, 2021 2020 Income (loss) before provision for (benefit from) income taxes $ (492) $ 1,404 Provision for (benefit from) income taxes 308 (2,048) Effective tax rate (62.6) % (145.9) % |
Summary of Business and Signi_3
Summary of Business and Significant Accounting Policies - Narrative (Details) $ in Thousands | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2021USD ($)stateinsurance_carrier | Mar. 31, 2020USD ($) | Dec. 31, 2020USD ($) | |
Error Corrections and Prior Period Adjustments Restatement [Line Items] | |||
Number of health insurance carriers (more than) | insurance_carrier | 200 | ||
Number of states in which the Company is licensed to market and sell health insurance | state | 50 | ||
Total stock-based compensation expense | $ 11,402 | $ 8,714 | |
Cost of revenue | 996 | 1,138 | |
Decrease in net income (loss) | 800 | $ (3,452) | |
Under-Recognition Of Stock-Based Compensation Expense | |||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | |||
Total stock-based compensation expense | $ 3,000 | ||
Out-Of-Period Adjustments | |||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | |||
Decrease in net income (loss) | $ 1,500 | ||
License | Over-Recognition Of Licensing Costs | |||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | |||
Cost of revenue | $ 1,500 |
Revenue - Disaggregation of Rev
Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Disaggregation of Revenue [Line Items] | ||
Total revenue | $ 134,214 | $ 106,408 |
Medicare | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 113,483 | 89,178 |
Medicare | Medicare Advantage | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 103,525 | 68,347 |
Medicare | Medicare Supplement | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 8,222 | 15,170 |
Medicare | Medicare Part D | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 1,736 | 5,661 |
Individual and Family | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 5,467 | 2,656 |
Individual and Family | Non-Qualified Health Plans | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 3,367 | 1,446 |
Individual and Family | Qualified Health Plans | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 2,100 | 1,210 |
Ancillary | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 3,724 | 4,251 |
Ancillary | Short-term | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 1,756 | 2,216 |
Ancillary | Dental | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 1,728 | 743 |
Ancillary | Vision | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 205 | 243 |
Ancillary | Other | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 35 | 1,049 |
Small Business | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 3,223 | 2,971 |
Commission Bonus | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 1,155 | 613 |
Commission | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 127,052 | 99,669 |
Other | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 7,162 | 6,739 |
Other | Sponsorship and Advertising Revenue | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 5,814 | 5,890 |
Other | Other | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | $ 1,348 | $ 849 |
Revenue - Commission Revenue by
Revenue - Commission Revenue by Segment (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Disaggregation of Revenue [Line Items] | ||
Total revenue | $ 134,214 | $ 106,408 |
Basic (in dollars per share) | $ (0.03) | $ 0.14 |
Diluted (in dollars per share) | $ (0.03) | $ 0.13 |
Commission | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | $ 127,052 | $ 99,669 |
Commission revenue from members approved during the period | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 121,073 | 86,921 |
Net commission revenue adjustments from members approved in prior period | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | $ 3,292 | $ 10,352 |
Basic (in dollars per share) | $ 0.12 | $ 0.42 |
Diluted (in dollars per share) | $ 0.12 | $ 0.40 |
Commission revenue from renewals of small business members during the period | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | $ 2,687 | $ 2,396 |
Medicare | Commission | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 114,692 | 90,104 |
Medicare | Commission revenue from members approved during the period | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 114,678 | 81,125 |
Medicare | Net commission revenue adjustments from members approved in prior period | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 14 | 8,979 |
Medicare | Commission revenue from renewals of small business members during the period | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 0 | 0 |
Individual, Family and Small Business | Commission | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 12,360 | 9,565 |
Individual, Family and Small Business | Commission revenue from members approved during the period | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 6,395 | 5,796 |
Individual, Family and Small Business | Net commission revenue adjustments from members approved in prior period | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 3,278 | 1,373 |
Decrease in revenue | (900) | |
Individual, Family and Small Business | Commission revenue from renewals of small business members during the period | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | $ 2,687 | $ 2,396 |
Supplemental Financial Statem_3
Supplemental Financial Statement Information- Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 | Mar. 31, 2020 | Dec. 31, 2019 |
Balance Sheet Related Disclosures [Abstract] | ||||
Cash | $ 72,326 | $ 39,552 | ||
Cash equivalents | 19,924 | 4,207 | ||
Cash and cash equivalents | 92,250 | 43,759 | ||
Restricted cash | 3,354 | 3,354 | ||
Total cash, cash equivalents and restricted cash | $ 95,604 | $ 47,113 | $ 187,520 | $ 26,820 |
Supplemental Financial Statem_4
Supplemental Financial Statement Information - Narrative (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Cash and Cash Equivalents [Line Items] | ||
Restricted cash | $ 3,354 | $ 3,354 |
China | ||
Cash and Cash Equivalents [Line Items] | ||
Deposits | $ 3,500 |
Supplemental Financial Statem_5
Supplemental Financial Statement Information - Schedule of Allowance for Credit Loss (Details) $ in Thousands | 3 Months Ended |
Mar. 31, 2021USD ($) | |
Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward] | |
Beginning balance | $ 2,026 |
Change in allowance | (78) |
Ending balance | $ 1,948 |
Supplemental Financial Statem_6
Supplemental Financial Statement Information - Schedule of Commissions Receivable (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Change in Contract with Customer, Asset [Roll Forward] | ||
Beginning balance | $ 792,405 | $ 589,222 |
Total revenue | 134,214 | 106,408 |
Cash receipts | (177,532) | (126,542) |
Change in credit loss allowance | (78) | (1,632) |
Ending balance | 741,847 | 560,717 |
Medicare | ||
Change in Contract with Customer, Asset [Roll Forward] | ||
Beginning balance | 739,637 | 550,922 |
Cash receipts | (165,520) | (112,731) |
Change in credit loss allowance | (72) | (1,574) |
Ending balance | 688,737 | 526,721 |
Individual, Family and Small Business | ||
Change in Contract with Customer, Asset [Roll Forward] | ||
Beginning balance | 52,768 | 38,300 |
Cash receipts | (12,012) | (13,811) |
Change in credit loss allowance | (6) | (58) |
Ending balance | 53,110 | 33,996 |
Commission revenue from members approved during the period | ||
Change in Contract with Customer, Asset [Roll Forward] | ||
Total revenue | 121,073 | 86,921 |
Commission revenue from members approved during the period | Medicare | ||
Change in Contract with Customer, Asset [Roll Forward] | ||
Total revenue | 114,678 | 81,125 |
Commission revenue from members approved during the period | Individual, Family and Small Business | ||
Change in Contract with Customer, Asset [Roll Forward] | ||
Total revenue | 6,395 | 5,796 |
Commission revenue from renewals of small business members during the period | ||
Change in Contract with Customer, Asset [Roll Forward] | ||
Total revenue | 2,687 | 2,396 |
Commission revenue from renewals of small business members during the period | Medicare | ||
Change in Contract with Customer, Asset [Roll Forward] | ||
Total revenue | 0 | 0 |
Commission revenue from renewals of small business members during the period | Individual, Family and Small Business | ||
Change in Contract with Customer, Asset [Roll Forward] | ||
Total revenue | 2,687 | 2,396 |
Net commission revenue adjustments from members approved in prior period | ||
Change in Contract with Customer, Asset [Roll Forward] | ||
Total revenue | 3,292 | 10,352 |
Net commission revenue adjustments from members approved in prior period | Medicare | ||
Change in Contract with Customer, Asset [Roll Forward] | ||
Total revenue | 14 | 8,979 |
Net commission revenue adjustments from members approved in prior period | Individual, Family and Small Business | ||
Change in Contract with Customer, Asset [Roll Forward] | ||
Total revenue | $ 3,278 | $ 1,373 |
Supplemental Financial Statem_7
Supplemental Financial Statement Information - Schedule of Credit Risk (Details) - Customer Concentration Risk - Accounts Receivable | 3 Months Ended | 12 Months Ended |
Mar. 31, 2021 | Dec. 31, 2020 | |
UnitedHealthcare | ||
Concentration Risk [Line Items] | ||
Major customer revenue, percentage | 21.00% | 21.00% |
Humana | ||
Concentration Risk [Line Items] | ||
Major customer revenue, percentage | 21.00% | 21.00% |
Aetna | ||
Concentration Risk [Line Items] | ||
Major customer revenue, percentage | 20.00% | 20.00% |
Centene | ||
Concentration Risk [Line Items] | ||
Major customer revenue, percentage | 12.00% | 11.00% |
Supplemental Financial Statem_8
Supplemental Financial Statement Information - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Balance Sheet Related Disclosures [Abstract] | ||
Prepaid maintenance contracts | $ 6,583 | $ 7,715 |
Prepaid expenses | 4,095 | 6,628 |
Prepaid insurance | 1,031 | 1,672 |
Others | 616 | 646 |
Prepaid expenses and other current assets | $ 12,325 | $ 16,661 |
Fair Value Measurements - Summa
Fair Value Measurements - Summary of Financial Assets (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Assets | ||
Short-term marketable securities | $ 33,922 | $ 49,620 |
Level 1 | Recurring | ||
Assets | ||
Total assets measured at fair value | 5,602 | 4,207 |
Level 2 | Recurring | ||
Assets | ||
Total assets measured at fair value | 48,244 | 49,620 |
Level 3 | Recurring | ||
Assets | ||
Total assets measured at fair value | 0 | 0 |
Carrying Value | Recurring | ||
Assets | ||
Total assets measured at fair value | 53,846 | 53,827 |
Fair Value | Recurring | ||
Assets | ||
Total assets measured at fair value | 53,846 | 53,827 |
Agency bonds | ||
Assets | ||
Short-term marketable securities | 26,826 | |
Agency bonds | Level 1 | Recurring | ||
Assets | ||
Short-term marketable securities | 0 | 0 |
Agency bonds | Level 2 | Recurring | ||
Assets | ||
Short-term marketable securities | 26,826 | 35,423 |
Agency bonds | Level 3 | Recurring | ||
Assets | ||
Short-term marketable securities | 0 | 0 |
Agency bonds | Carrying Value | Recurring | ||
Assets | ||
Short-term marketable securities | 26,826 | 35,423 |
Agency bonds | Fair Value | Recurring | ||
Assets | ||
Short-term marketable securities | 26,826 | 35,423 |
Commercial paper | ||
Assets | ||
Short-term marketable securities | 7,096 | |
Commercial paper | Level 1 | Recurring | ||
Assets | ||
Short-term marketable securities | 0 | 0 |
Commercial paper | Level 2 | Recurring | ||
Assets | ||
Short-term marketable securities | 7,096 | 14,197 |
Commercial paper | Level 3 | Recurring | ||
Assets | ||
Short-term marketable securities | 0 | 0 |
Commercial paper | Carrying Value | Recurring | ||
Assets | ||
Short-term marketable securities | 7,096 | 14,197 |
Commercial paper | Fair Value | Recurring | ||
Assets | ||
Short-term marketable securities | 7,096 | 14,197 |
Money market funds | ||
Assets | ||
Cash equivalents | 5,602 | |
Money market funds | Level 1 | Recurring | ||
Assets | ||
Cash equivalents | 5,602 | 4,207 |
Money market funds | Level 2 | Recurring | ||
Assets | ||
Cash equivalents | 0 | 0 |
Money market funds | Level 3 | Recurring | ||
Assets | ||
Cash equivalents | 0 | 0 |
Money market funds | Carrying Value | Recurring | ||
Assets | ||
Cash equivalents | 5,602 | 4,207 |
Money market funds | Fair Value | Recurring | ||
Assets | ||
Cash equivalents | 5,602 | $ 4,207 |
Commercial paper | ||
Assets | ||
Cash equivalents | 14,322 | |
Commercial paper | Level 1 | Recurring | ||
Assets | ||
Cash equivalents | 0 | |
Commercial paper | Level 2 | Recurring | ||
Assets | ||
Cash equivalents | 14,322 | |
Commercial paper | Level 3 | Recurring | ||
Assets | ||
Cash equivalents | 0 | |
Commercial paper | Carrying Value | Recurring | ||
Assets | ||
Cash equivalents | 14,322 | |
Commercial paper | Fair Value | Recurring | ||
Assets | ||
Cash equivalents | $ 14,322 |
Fair Value Measurements - Contr
Fair Value Measurements - Contractual Maturities (Details) $ in Thousands | Mar. 31, 2021USD ($) |
Amortized Cost | |
Due in 1 year | $ 53,827 |
Fair Value | |
Due in 1 year | $ 53,846 |
Fair Value Measurements - Unrea
Fair Value Measurements - Unrealized Gains and Losses (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Cash equivalents | ||
Cash and cash equivalents | $ 92,250 | $ 43,759 |
Short-term marketable securities | ||
Fair Value | 33,922 | $ 49,620 |
Total | 53,827 | |
Unrealized Gain | 21 | |
Unrealized Loss | (2) | |
Fair Value | 53,846 | |
Money market funds | ||
Cash equivalents | ||
Cash and cash equivalents | 5,602 | |
Unrealized Gain | 0 | |
Unrealized Loss | 0 | |
Fair Value | 5,602 | |
Commercial paper | ||
Cash equivalents | ||
Cash and cash equivalents | 14,323 | |
Unrealized Gain | 0 | |
Unrealized Loss | (1) | |
Fair Value | 14,322 | |
Agency bonds | ||
Short-term marketable securities | ||
Amortized Cost | 26,805 | |
Unrealized Gain | 21 | |
Unrealized Loss | 0 | |
Fair Value | 26,826 | |
Commercial paper | ||
Short-term marketable securities | ||
Amortized Cost | 7,097 | |
Unrealized Gain | 0 | |
Unrealized Loss | (1) | |
Fair Value | $ 7,096 |
Fair Value Measurements - Narra
Fair Value Measurements - Narrative (Details) | Mar. 31, 2021security |
Fair Value Disclosures [Abstract] | |
Number of securities in net loss positions | 12 |
Equity - Narrative (Details)
Equity - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions | 1 Months Ended | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2021 | Dec. 31, 2020 | |
Equity, Class of Treasury Stock [Line Items] | |||
Sale of stock, shares issued (in shares) | 2,100,000 | ||
Sale of stock, price per share (in dollars per share) | $ 115 | ||
Net proceeds from sale of stock | $ 228 | ||
Number of shares repurchased under share repurchase plan (in shares) | 0 | ||
Treasury shares that were previously surrendered by employees to satisfy tax withholdings (in shares) | 1,200,000 | ||
Treasury stock (in shares) | 11,900,000 | 11,800,000 | |
Over-Allotment Option | |||
Equity, Class of Treasury Stock [Line Items] | |||
Sale of stock, shares issued (in shares) | 300,000 | ||
Previous share repurchase programs | |||
Equity, Class of Treasury Stock [Line Items] | |||
Number of shares repurchased under share repurchase plan (in shares) | 10,700,000 |
Equity - Schedule of Stock-Base
Equity - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Total stock-based compensation expense | $ 11,402 | $ 8,714 |
Amount capitalized in internal-use software | 550 | 248 |
Total stock-based compensation | 11,952 | 8,962 |
Common stock options | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Total stock-based compensation expense | 180 | 306 |
Restricted stock units | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Total stock-based compensation expense | 10,719 | 8,408 |
ESPP | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Total stock-based compensation expense | 503 | 0 |
Marketing and advertising | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Total stock-based compensation expense | 2,485 | 1,730 |
Customer care and enrollment | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Total stock-based compensation expense | 469 | 662 |
Technology and content | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Total stock-based compensation expense | 2,743 | 1,617 |
General and administrative | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Total stock-based compensation expense | $ 5,705 | $ 4,705 |
Net Income (Loss) Per Share - C
Net Income (Loss) Per Share - Computation of Basic and Diluted Net Income per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Numerator: | ||
Net income (loss) | $ (800) | $ 3,452 |
Denominator: | ||
Shares used in per share calculation - basic (in shares) | 26,620 | 24,719 |
Dilutive effect of common stock (in shares) | 0 | 1,460 |
Total common stock shares used in diluted share calculation (in shares) | 26,620 | 26,179 |
Net income (loss) per share - basic (in usd per share) | $ (0.03) | $ 0.14 |
Net income (loss) per share - diluted (in usd per share) | $ (0.03) | $ 0.13 |
Net Income (Loss) Per Share - S
Net Income (Loss) Per Share - Schedule of Anti-Dilutive Shares Excluded from Computation Of Net Income Per Share (Details) shares in Thousands | 3 Months Ended |
Mar. 31, 2021shares | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |
Antidilutive securities (in shares) | 1,460 |
Common stock options | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |
Antidilutive securities (in shares) | 363 |
Restricted stock units | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |
Antidilutive securities (in shares) | 1,090 |
ESPP | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |
Antidilutive securities (in shares) | 7 |
Commitments and Contingencies_2
Commitments and Contingencies (Details) $ in Thousands | Jul. 01, 2019plaintiff | Apr. 30, 2020claim | Oct. 13, 2020plaintiff | Mar. 31, 2021USD ($) |
Loss Contingencies [Line Items] | ||||
Remainder of 2021 | $ 4,246 | |||
2022 | 3,472 | |||
2023 | 2,745 | |||
2024 | 2,056 | |||
2025 | 1,353 | |||
Thereafter | 1,353 | |||
Total | $ 15,225 | |||
New claims filed | 2 | 2 | ||
Le'Vias Compliant | ||||
Loss Contingencies [Line Items] | ||||
Number of plaintiffs | plaintiff | 2 |
Segment and Geographic Inform_3
Segment and Geographic Information - Segment Operating Results (Details) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021USD ($)segment | Mar. 31, 2020USD ($) | |
Segment Reporting Information [Line Items] | ||
Number of operating segments | segment | 2 | |
Total revenue | $ 134,214 | $ 106,408 |
Stock-based compensation expense | (11,402) | (8,714) |
Depreciation and amortization | (3,944) | (2,324) |
Amortization of intangible assets | (176) | (547) |
Restructuring charges | (2,431) | 0 |
Other income, net | 150 | 373 |
Income (loss) before provision for (benefit from) income taxes | (492) | 1,404 |
Amortization of internally developed software | 2,806 | 1,501 |
Operating Segments | ||
Segment Reporting Information [Line Items] | ||
Total revenue | 134,214 | 106,408 |
Segment profit (loss) | 32,597 | 26,064 |
Operating Segments | Medicare | ||
Segment Reporting Information [Line Items] | ||
Total revenue | 121,021 | 96,151 |
Segment profit (loss) | 24,545 | 23,136 |
Operating Segments | Individual, Family and Small Business | ||
Segment Reporting Information [Line Items] | ||
Total revenue | 13,193 | 10,257 |
Segment profit (loss) | 8,052 | 2,928 |
Corporate | ||
Segment Reporting Information [Line Items] | ||
Segment profit (loss) | $ (15,286) | $ (13,448) |
Segment and Geographic Inform_4
Segment and Geographic Information - Schedule Of Long-Lived Assets By Geographical Area (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Segment Reporting Information [Line Items] | ||
Long-lived assets | $ 42,340 | $ 41,065 |
United States | ||
Segment Reporting Information [Line Items] | ||
Long-lived assets | 41,829 | 40,500 |
China | ||
Segment Reporting Information [Line Items] | ||
Long-lived assets | $ 511 | $ 565 |
Segment and Geographic Inform_5
Segment and Geographic Information - Schedule of Revenue by Major Customers (Details) - Customer Concentration Risk - Revenue | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
UnitedHealthcare | ||
Revenue, Major Customer [Line Items] | ||
Major customer revenue, percentage | 22.00% | 22.00% |
Aetna | ||
Revenue, Major Customer [Line Items] | ||
Major customer revenue, percentage | 21.00% | 15.00% |
Humana | ||
Revenue, Major Customer [Line Items] | ||
Major customer revenue, percentage | 17.00% | 19.00% |
Centene | ||
Revenue, Major Customer [Line Items] | ||
Major customer revenue, percentage | 12.00% | 11.00% |
Leases - Narrative (Details)
Leases - Narrative (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Lessee, Lease, Description [Line Items] | ||
Operating lease cost | $ 2 | $ 2.1 |
Minimum | ||
Lessee, Lease, Description [Line Items] | ||
Remaining lease term | 3 years | |
Maximum | ||
Lessee, Lease, Description [Line Items] | ||
Remaining lease term | 9 years |
Leases - Supplemental Balance S
Leases - Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Leases [Abstract] | ||
Operating lease right-of-use assets | $ 41,284 | $ 42,558 |
Lease liabilities – current | 5,316 | 5,192 |
Lease liabilities – non-current | 39,984 | 41,369 |
Total operating lease liabilities | $ 45,300 | $ 46,561 |
Leases - Supplemental Informati
Leases - Supplemental Information (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended |
Mar. 31, 2021 | Dec. 31, 2020 | |
Leases [Abstract] | ||
Operating cash outflows from operating leases | $ 1,900 | $ 7,090 |
Weighted-average remaining lease term of operating leases | 7 years | 7 years 2 months 12 days |
Weighted-average discount rate used to recognize operating lease right-of-use-assets | 5.40% | 5.40% |
Leases - Maturities of Lease Li
Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Operating leases | ||
Remainder of 2021 | $ 5,744 | |
2022 | 7,701 | |
2023 | 8,033 | |
2024 | 7,832 | |
2025 | 8,009 | |
Thereafter | 19,407 | |
Total lease payments | 56,726 | |
Less imputed interest | (11,426) | |
Total | 45,300 | $ 46,561 |
Sublease income, remainder of 2021 | 900 | |
Sublease income, 2022 | 400 | |
Sublease income, 2023 | $ 400 |
Restructuring (Details)
Restructuring (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | |
Feb. 28, 2021employee | Mar. 31, 2021USD ($) | Mar. 31, 2020USD ($) | |
Restructuring and Related Activities [Abstract] | |||
Positions eliminated | employee | 89 | ||
Percentage of total workforce | 5.00% | ||
Restructuring charges | $ 2,431 | $ 0 | |
Accrued restructuring charges | $ 300 |
Debt (Details)
Debt (Details) - USD ($) | Dec. 20, 2019 | Sep. 17, 2018 | Mar. 31, 2021 | Dec. 31, 2020 |
Debt Instrument [Line Items] | ||||
Borrowings under line of credit | $ 0 | |||
Credit Agreement Amendment | ||||
Debt Instrument [Line Items] | ||||
Debt issuance costs | 500,000 | |||
Revolving Credit Facility | ||||
Debt Instrument [Line Items] | ||||
Borrowing capacity | $ 75,000,000 | $ 40,000,000 | ||
Commitment fee percentage | 0.50% | |||
Facility fee percentage | 0.50% | 1.75% | ||
Maximum borrowing capacity | $ 75,000,000 | $ 40,000,000 | ||
Covenant, minimum cash and cash equivalents | 6,000,000 | 6,000,000 | ||
Covenant, maximum cash and cash equivalents | 11,300,000 | |||
Minimum liquidity | 10,000,000 | |||
Maximum liquidity | $ 18,800,000 | |||
Debt issuance costs | 1,200,000 | |||
Revolving Credit Facility | Credit Agreement Amendment | ||||
Debt Instrument [Line Items] | ||||
Debt issuance costs | $ 700,000 | $ 700,000 | ||
Letter of Credit | ||||
Debt Instrument [Line Items] | ||||
Borrowing capacity | $ 5,000,000 | |||
Eligible Commissions Receivables, Preceding Three Months | Revolving Credit Facility | ||||
Debt Instrument [Line Items] | ||||
Borrowing base percentage | 80.00% | |||
Eligible Commissions Receivables, Succeeding Three Months | Revolving Credit Facility | ||||
Debt Instrument [Line Items] | ||||
Borrowing base percentage | 80.00% | |||
Eligible Commissions Receivables, Succeeding Six Months | Revolving Credit Facility | ||||
Debt Instrument [Line Items] | ||||
Borrowing base percentage | 50.00% |
Income Taxes - Summary of Incom
Income Taxes - Summary of Income Tax Benefit (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Income Tax Disclosure [Abstract] | ||
Income (loss) before provision for (benefit from) income taxes | $ (492) | $ 1,404 |
Provision for (benefit from) income taxes | $ 308 | $ (2,048) |
Effective tax rate | (62.60%) | (145.90%) |
Income Taxes - Narrative (Detai
Income Taxes - Narrative (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Income Tax Disclosure [Abstract] | ||
Provision for (benefit from) income taxes | $ 308 | $ (2,048) |
Effective tax rate | (62.60%) | (145.90%) |
Subsequent Event (Details)
Subsequent Event (Details) - USD ($) $ / shares in Units, $ in Millions | Apr. 30, 2021 | Mar. 31, 2020 |
Subsequent Event [Line Items] | ||
Sale of stock, shares issued (in shares) | 2,100,000 | |
Sale of stock, price per share (in dollars per share) | $ 115 | |
Net proceeds from sale of stock | $ 228 | |
Subsequent Event | ||
Subsequent Event [Line Items] | ||
Sale of stock, shares issued (in shares) | 2,250,000 | |
Preferred Stock, par value (in dollars per share) | $ 0.001 | |
Gross proceeds from sale of stock | $ 225 | |
Sale of stock, price per share (in dollars per share) | $ 100 | |
Net proceeds from sale of stock | $ 216.2 |
Uncategorized Items - ehth-2021
Label | Element | Value |
Accounting Standards Update [Extensible List] | us-gaap_AccountingStandardsUpdateExtensibleList | us-gaap:AccountingStandardsUpdate201613Member |